Hi @dachopper,
re your comment " Because... Adult Gvhd is 5 times the number of patients than pediatric", I think you'll find it's even better than that.
The exact quote from CEO Itescu (Feb 28, 2024 Earnings Call) was:
" For adult steroid-refractory acute GVHD, we are collaborating ... to conduct a pivotal trial in adults with this condition in patients who have failed second-line therapies and have no approved therapeutics. This potential market is 5x larger than for pediatric. " (underlining added for emphasis)
and again:
" For adults, adolescents and adults over the age of 12, ruxolitinib is the only approved therapy. And 45% of those who receive ruxolitinib are nonresponders. For the nonresponders, there are no approved therapies."
In other words, it is the adult Ruxolitinib 'non-responder' market ALONE which is 5 x larger than the market for the paediatric indication i.e. those sometimes characterised as RR-aGVHD.
A significant & yet unestimated part of the adult market for SR - aGVHD treatments may 'respond' to Ruxolitinib, and yet attending physicicans may have reservations or outright concerns/ fears about prescribing Ruxolitinib as treatment given it's undeniable toxicity, adverse event profile & Novartis/ Incyte's squirrely behaviour when it comes to producing long-term overall survival i.e. mortality/ morbidity data.
I think we'll find the paradigm shift will generate its own momentum & there will be little need to promote RYONCIL for off-label use.
Cheers
GLTA(LT)H
- Forums
- ASX - By Stock
- MSB
- 2024 Here we go again.
2024 Here we go again., page-496
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.05 |
Change
0.020(1.95%) |
Mkt cap ! $1.198B |
Open | High | Low | Value | Volume |
$1.02 | $1.07 | $1.02 | $4.325M | 4.155M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 106783 | $1.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.05 | 134238 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 121599 | 1.035 |
29 | 181957 | 1.030 |
19 | 289337 | 1.025 |
21 | 303196 | 1.020 |
10 | 563139 | 1.015 |
Price($) | Vol. | No. |
---|---|---|
1.040 | 56863 | 16 |
1.045 | 150529 | 19 |
1.050 | 40939 | 12 |
1.055 | 91264 | 11 |
1.060 | 139511 | 7 |
Last trade - 12.59pm 07/06/2024 (20 minute delay) ? |
|
|||||
Last
$1.04 |
  |
Change
0.020 ( 0.92 %) |
|||
Open | High | Low | Volume | ||
$1.02 | $1.07 | $1.02 | 810296 | ||
Last updated 13.21pm 07/06/2024 ? |
Featured News
MSB (ASX) Chart |